Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239139 | 0.94 | MAPKAPK2 (0.31) | — | |
| SCHEMBL4697332 | 0.87 | SYK (0.34) | SYKPDPK1 | |
| SCHEMBL4696451 | 0.77 | SYK (0.38) | SYK | |
| SCHEMBL4697306 | 0.73 | KDM4E (0.35) | ALDH1A1GLA | |
| SCHEMBL22485954 | 0.71 | CYP11B2 (0.33) | PDPK1 | |
| SCHEMBL8303054 | 0.69 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL22932340 | 0.67 | SYK (0.46) | SYKPDPK1 | |
| SCHEMBL25263548 | 0.67 | GPR119 (0.41) | PDPK1 | |
| SCHEMBL13195655 | 0.67 | USP30 (0.32) | PDPK1 | |
| SCHEMBL31349701 | 0.67 | USP30 (0.32) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954673-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | Sanofi-Aventis Deutschland GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007059871-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-31 | — | — | WO | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096357-A1 | Novel pleuromutilin derivatives | FABP2, PLEC, MLNR | SYK 2559/4885PDPK1 2777/4885ALDH1A1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.